Related Articles
ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma
Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma
Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib
Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid
Role of mTOR signaling in the regulation of high glucose‑induced podocyte injury